Patents by Inventor Jason Arnold Lotvin
Jason Arnold Lotvin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952597Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.Type: GrantFiled: July 7, 2020Date of Patent: April 9, 2024Assignee: Pfizer Inc.Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
-
Publication number: 20240016915Abstract: The invention relates to methods for producing an RSV F protein trimer in a fed batch cell culture.Type: ApplicationFiled: September 30, 2021Publication date: January 18, 2024Applicant: Pfizer Inc.Inventors: Shelby Hutchins BREEN, Cameron Albert HARRINGTON, Michaela Evelina JACOBS, Jason Arnold LOTVIN, Bhanu Chandra MULUKUTLA, David STEAD, Madhuresh SUMIT
-
Publication number: 20230405137Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.Type: ApplicationFiled: November 4, 2021Publication date: December 21, 2023Inventors: Paul Wayne Brown, Kaushik Dutta, Jason Arnold Lotvin, Kelly Jeffrey Sackett
-
Publication number: 20230000966Abstract: In one aspect, the invention relates to a polypeptide derived from E. coli and a fragment thereof, including compositions and methods thereof. Also disclosed herein are compositions that include a polypeptide derived from E. coli and a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. In a further aspect, disclosed herein are mammalian host cells that include sequence(s) encoding a polypeptide derived from E. coli or fragments thereof.Type: ApplicationFiled: October 28, 2020Publication date: January 5, 2023Inventors: Annaliesa Sybil Anderson, Ye Che, Wei Chen, Laurent Oliver Chorro, Ling Chu, Robert G.K. Donald, Matthew Curtis Griffor, Jianxin Gu, Zeqiang Guan, Jin-Hwan Kim, Srinivas Kodali, Scott Ellis Lomberk, Jason Arnold Lotvin, Nishith Merchant, Justin Keith Moran, Rosalind Pan, Avvari Krishna Prasad, Mark Edward Ruppen, Suddham Singh, David Robert Stead, Karen Kiyoko Takane
-
Publication number: 20220168410Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.Type: ApplicationFiled: February 15, 2022Publication date: June 2, 2022Applicant: Pfizer Inc.Inventors: Robert G.K. Donald, Annaliesa Sybil Anderson, Laurent Oliver Chorro, Jianxin Gu, Jin-Hwan Kim, Srinivas Kodali, Jason Arnold Lotvin, Justin Keith Moran, Rosalind Pan, Avvari Krishna Prasad, Mark Edward Ruppen, Suddham Singh, Ling Chu, Scott Ellis Lomberk, Karen Kiyoko Takane, Nishith Merchant, Wei Chen
-
Patent number: 11260119Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.Type: GrantFiled: August 7, 2019Date of Patent: March 1, 2022Assignee: Pfizer Inc.Inventors: Robert G. K. Donald, Annaliesa Sybil Anderson, Laurent Oliver Chorro, Jianxin Gu, Jin-Hwan Kim, Srinivas Kodali, Jason Arnold Lotvin, Justin Keith Moran, Rosalind Pan, Avvari Krishna Prasad, Mark Edward Ruppen, Suddham Singh, Ling Chu, Scott Ellis Lomberk, Karen Kiyoko Takane, Nishith Merchant, Wei Chen
-
Patent number: 11208633Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.Type: GrantFiled: December 5, 2019Date of Patent: December 28, 2021Assignee: Pfizer Inc.Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
-
Publication number: 20210180008Abstract: The present invention relates to media and fermentation methods for producing polysaccharides in bacterial cell culture. In one aspect, the invention relates to a complex culture medium comprising a vegetable hydrolysate, a yeast extract, and a carbon source. In another aspect, the invention relates to a defined media having a total amino acid concentration greater than about 50 mM. A further aspect of the invention relates to the use of fed batch and perfusion fermentation methods for cultivating polysaccharide-producing bacteria.Type: ApplicationFiled: February 8, 2021Publication date: June 17, 2021Applicant: Pfizer Inc.Inventors: Sunil Gururao Desai, Michael Allen Hanson, Jonathan Patrick Kinross, Daniel R. Lasko, Scott Ellis Lomberk, Jason Arnold Lotvin, Sujata Kaushikbhai Patel-Brown, Weiqiang Sun, Peter Anthony Tomasello
-
Patent number: 10982198Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.Type: GrantFiled: August 19, 2018Date of Patent: April 20, 2021Assignee: Pfizer Inc.Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
-
Patent number: 10947494Abstract: The present invention relates to media and fermentation methods for producing polysaccharides in bacterial cell culture. In one aspect, the invention relates to a complex culture medium comprising a vegetable hydrolysate, a yeast extract, and a carbon source. In another aspect, the invention relates to a defined media having a total amino acid concentration greater than about 50 mM. A further aspect of the invention relates to the use of fed batch and perfusion fermentation methods for cultivating polysaccharide-producing bacteria.Type: GrantFiled: November 10, 2016Date of Patent: March 16, 2021Assignee: Pfizer Inc.Inventors: Sunil Gururao Desai, Michael Allen Hanson, Jonathan Patrick Kinross, Daniel R. Lasko, Scott Ellis Lomberk, Jason Arnold Lotvin, Sujata Kaushikbhai Patel-Brown, Weiqiang Sun, Peter Anthony Tomasello
-
Publication number: 20210024903Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.Type: ApplicationFiled: July 7, 2020Publication date: January 28, 2021Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
-
Patent number: 10787652Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.Type: GrantFiled: October 7, 2013Date of Patent: September 29, 2020Assignee: Pfizer Inc.Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
-
Publication number: 20200165582Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.Type: ApplicationFiled: December 5, 2019Publication date: May 28, 2020Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G.K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
-
Publication number: 20200061177Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.Type: ApplicationFiled: August 7, 2019Publication date: February 27, 2020Inventors: Robert G.K. Donald, Annaliesa Sybil Anderson, Laurent Oliver Chorro, Jianxin Gu, Jin-Hwan Kim, Srinivas Kodali, Jason Arnold Lotvin, Justin Keith Moran, Rosalind Pan, Avvari Krishna Prasad, Mark Edward Ruppen, Suddham Singh, Ling Chu, Scott Ellis Lomberk, Karen Kiyoko Takane, Nishith Merchant, Wei Chen
-
Publication number: 20190292513Abstract: The present invention relates to media and fermentation methods for producing polysaccharides in bacterial cell culture. In one aspect, the invention relates to a complex culture medium comprising a vegetable hydrolysate, a yeast extract, and a carbon source. In another aspect, the invention relates to a defined media having a total amino acid concentration greater than about 50 mM. A further aspect of the invention relates to the use of fed batch and perfusion fermentation methods for cultivating polysaccharide-producing bacteria.Type: ApplicationFiled: November 10, 2016Publication date: September 26, 2019Inventors: Sunil Gururao Desai, Michael Allen Hanson, Jonathan Patrick Kinross, Daniel R. Lasko, Scott Ellis Lomberk, Jason Arnold Lotvin, Sujata Kaushikbhai Patel-Brown, Weiqiang Sun, Peter Anthony Tomasello
-
Publication number: 20190112584Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.Type: ApplicationFiled: August 19, 2018Publication date: April 18, 2019Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
-
Publication number: 20150291940Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.Type: ApplicationFiled: October 7, 2013Publication date: October 15, 2015Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
-
Patent number: 8247211Abstract: The invention provides compounds of formula Wherein R1, R2, R3, R4, R5, R6a, R6b, R6c, R6d, R6e and R7 are defined in the specification. These compounds are useful as antibiotic agents.Type: GrantFiled: February 8, 2011Date of Patent: August 21, 2012Assignees: American Cyanamid Company, Wyeth Holdings CorporationInventors: Jason Arnold Lotvin, Mark Edward Ruppen
-
Publication number: 20110151546Abstract: The invention provides compounds of formula Wherein R1, R2, R3, R4, R5, R6a, R6b, R6c, R6d, R6e and R7 are defined in the specification. These compounds are useful as antibiotic agents.Type: ApplicationFiled: February 8, 2011Publication date: June 23, 2011Applicants: AMERICAN CYANAMID COMPANY, Wyeth Holdings CorporationInventors: Jason Arnold Lotvin, Mark Edward Ruppen
-
Patent number: 7718791Abstract: A process for reducing the protein content and preserving the capsular polysaccharide content in a complex cellular Streptococcus pneumoniae lysate broth prior to purification is described. Utilizing pH reduction after cellular lysis has resulted in a purified polysaccharide that consistently meets the protein specification, and higher recovery yields of polysaccharide during the purification process.Type: GrantFiled: March 31, 2006Date of Patent: May 18, 2010Assignee: Wyeth LLCInventors: Brian Bahler, Tsu-shun Lee, Jason Arnold Lotvin, Mark Edward Ruppen, Pamela Sue Fink Charbonneau